These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 6714290)

  • 21. Hydralazine kinetics after single and repeated oral doses.
    Shepherd AM; Ludden TM; McNay JL; Lin MS
    Clin Pharmacol Ther; 1980 Dec; 28(6):804-11. PubMed ID: 7438695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of the acetylator phenotype for the clinical use of dihydralazine.
    Siegmund W; Franke G; Biebler KE; Donner I; Kallwellis R; Kairies M; Scherber A; Hüller H
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S74-8. PubMed ID: 3842694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical consequences of polymorphic acetylation of basic drugs.
    Drayer DE; Reidenberg MM
    Clin Pharmacol Ther; 1977 Sep; 22(3):251-8. PubMed ID: 19187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.
    Shen DD; Hosler JP; Schroder RL; Azarnoff DL
    J Pharmacokinet Biopharm; 1980 Feb; 8(1):53-68. PubMed ID: 7381691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension.
    Spinasse LB; Santos AR; Suffys PN; Muxfeldt ES; Salles GF
    Pharmacogenomics; 2014 Feb; 15(2):169-78. PubMed ID: 24444407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydralazine dose-response curve analysis.
    Graves DA; Muir KT; Richards W; Steiger BW; Chang I; Patel B
    J Pharmacokinet Biopharm; 1990 Aug; 18(4):279-91. PubMed ID: 2231320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug acetylation and expression of lupus erythematosus.
    Marsden JR; Mason GG; Coburn PR; Rawlins MD; Shuster S
    Eur J Clin Pharmacol; 1985; 28(4):387-90. PubMed ID: 4029245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydralazine, antinuclear antibodies, and the lupus syndrome.
    Mansilla-Tinoco R; Harland SJ; Ryan PJ; Bernstein RM; Dollery CT; Hughes GR; Bulpitt CJ; Morgan A; Jones JM
    Br Med J (Clin Res Ed); 1982 Mar; 284(6320):936-9. PubMed ID: 6802356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydralazine in arterial hypertension. Randomized double-blind comparison of conventional/Slow-Release formulation and of b.i.d./q.i.d. dosage regimens.
    Wulff K; Lenz K; Krogsgaard AR; Holst B
    Acta Med Scand; 1980; 208(1-2):49-54. PubMed ID: 7435247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective study of immunologic effects of hydralazine in hypertensive patients.
    Litwin A; Adams LE; Zimmer H; Foad B; Loggie JH; Hess EV
    Clin Pharmacol Ther; 1981 Apr; 29(4):447-56. PubMed ID: 6970646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kinetics of hydralazine and its main metabolites in slow and fast acetylators.
    Reece PA; Cozamanis I; Zacest R
    Clin Pharmacol Ther; 1980 Dec; 28(6):769-78. PubMed ID: 7438692
    [No Abstract]   [Full Text] [Related]  

  • 32. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility.
    Batchelor JR; Welsh KI; Tinoco RM; Dollery CT; Hughes GR; Bernstein R; Ryan P; Naish PF; Aber GM; Bing RF; Russell GI
    Lancet; 1980 May; 1(8178):1107-9. PubMed ID: 6103441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens.
    Ellard GA; Gammon PT
    Br J Clin Pharmacol; 1977 Feb; 4(1):5-14. PubMed ID: 843424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cadralazine challenge in patients with previous hydralazine-induced lupus: a 6-month study.
    Pålsson L; Weiner L; Englund G; Henning M
    Clin Pharmacol Ther; 1989 Aug; 46(2):177-81. PubMed ID: 2758727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between the genetically determined acetylator phenotype and DNA damage induced by hydralazine and 2-aminofluorene in cultured rabbit hepatocytes.
    McQueen CA; Maslansky CJ; Glowinski IB; Crescenzi SB; Weber WW; Williams GM
    Proc Natl Acad Sci U S A; 1982 Feb; 79(4):1269-72. PubMed ID: 6951172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hydralazine sensitivity: clinical features, autoantibody changes and HLA-DR phenotype.
    Russell GI; Bing RF; Jones JA; Thurston H; Swales JD
    Q J Med; 1987 Oct; 65(246):845-52. PubMed ID: 3329739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acetylation phenotype in hypertensive patients.
    Huang CY; Chu JY; Yen TC
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1992 Jan; 8(1):1-5. PubMed ID: 1548734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the sulphadimidine acetylator phenotyping test in patients with reduced renal function.
    Hall S
    Acta Med Scand; 1981; 209(6):505-7. PubMed ID: 7257867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acetylator phenotype and lupus erythematosus.
    Uetrecht JP; Woosley RL
    Clin Pharmacokinet; 1981; 6(2):118-34. PubMed ID: 7011656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Acetylator phenotype in spondylarthritis ankylopoietica].
    Rojkovich B; Genti G; Borbás E; Bálint G; Gömör B
    Orv Hetil; 1989 Dec; 130(49):2639-41. PubMed ID: 2689951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.